Sentinel lymph node biopsy rates in Victoria, 2018 and 2019.

Authors :: Watts, Caroline
Spillane, Andrew
Henderson, Michael A
Cust, Anne
Braithwaite, J
Gyorki, DE
Hong, AM
Kelly, JW
Long, GV
Mar, VJ
Menzies, AM
Morton, RL
Rapport, F
Saw, RPM
Schmid, H
Scolyer, RA
Smith, AL
Winder, A
Mann, GJ
Source :: Medical Journal of Australia; Aug2022, Vol. 217 Issue 4, p208-209, 2p
Publication Year :: 2022
Abstract: Keywords: Melanoma; Surgical oncology EN Melanoma Surgical oncology 208 209 2 08/17/22 20220815 NES 220815 Sentinel lymph node biopsy (SLNB) is a staging procedure for assessing metastatic spread from a primary melanoma to the draining lymph nodes. During 2018 and 2019, 892 of 1855 people diagnosed with invasive melanomas of greater than 1.0 mm thickness (48%) and 151 of 597 with melanomas of 0.8-1.0 mm thickness (25%) underwent SLNB. [Extracted from the article]